Loading
NASDAQHealthcareMedical - Devices
Latest quote
$9.02
−$0.14 · -1.53%
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
Latest quote
$9.02
−$0.14 · -1.53%
Regular session · ET · Market data may be delayed.
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
Day range
Current $9.02
52-week range
Current $9.02
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
37
Expensive
Sentiment
63
Bullish
Risk
68
High Risk
Momentum
22
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Senseonics Holdings, Inc. operates as a medical technology enterprise, specializing in the development and commercialization of continuous glucose monitoring (CGM) systems. These innovative solutions cater to individuals with diabetes across the United States, Europe, the Middle East, and Africa. The company's core product offerings, Eversense and Eversense XL, are advanced implantable CGM devices. They function by continuously tracking glucose levels through an under-the-skin sensor, a detachable and rechargeable smart transmitter, and an intuitive mobile application. This setup enables real-time diabetes monitoring and management for durations of up to half a year. Senseonics delivers its products and services to healthcare providers and patients alike via an extensive network of distributors and strategic fulfillment partners. Additionally, the firm maintains a collaborative agreement with the University Hospitals Accountable Care Organization. Founded in 1996, Senseonics Holdings, Inc. is headquartered in Germantown, Maryland.
Day range
Current $9.02
52-week range
Current $9.02
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 35.26M USD | 22.47M USD | 22.39M USD | 16.39M USD | 13.68M USD |
| Cost of goods sold | 19.49M USD | 21.94M USD | 19.3M USD | 13.66M USD | 14.49M USD |
| Gross profit | 15.76M USD | 533K USD | 3.09M USD | 2.73M USD | −811K USD |
| Research and development | 31.59M USD | 41.14M USD | 48.75M USD | 39.72M USD | 27.22M USD |
| Selling, general, and administrative | 52.51M USD | 34.23M USD | 29.94M USD | 31.63M USD | 29.15M USD |
| Operating expenses | 84.1M USD | 75.38M USD | 78.69M USD | 71.35M USD | 56.37M USD |
| Interest income | 4.2M USD | 4.5M USD | 5.36M USD | 1.82M USD | 243K USD |
| Interest expense | 4.95M USD | 8.44M USD | 11.11M USD | 18.7M USD | 16.72M USD |
| Depreciation and amortization | 1.51M USD | 1.48M USD | 1.28M USD | 985K USD | 1.24M USD |
| Operating income | −68.34M USD | −74.84M USD | −75.6M USD | −68.63M USD | −57.18M USD |
| Net income | −69.11M USD | −78.62M USD | −60.39M USD | 142.12M USD | −302.47M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Oct 20, 2025 | 1:20 | — | — |
Effective Oct 20, 2025
1:20
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI10.85M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM9.05M0.01%78.56B USD0.19%$277.57-0.05%
Vanguard Extended Market ETFVXF5.19M0.01%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO3.22M0.02%14.04B USD0.24%$353.47-0.53%
Schwab U.S. Small-Cap ETFSCHA2.38M0.01%21.7B USD0.03%$32.66+0.15%
Vanguard Russell 2000 ETFVTWO2.09M0.01%18B USD0.06%$112.1-0.10%
Invesco Dorsey Wright SmallCap Momentum ETFDWAS1.48M0.37%402.02M USD0.60%$105.76-0.09%
iShares Micro-Cap ETFIWC1.08M0.08%1.33B USD0.60%$182.79-0.31%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOSchwab U.S. Small-Cap ETFSCHAVanguard Russell 2000 ETFVTWOInvesco Dorsey Wright SmallCap Momentum ETFDWASiShares Micro-Cap ETFIWCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
